Stocks · News reference
Reported Earlier: 'India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease' - Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/india-approves-novo-nordisks-obesity-drug-wegovy-fatty-liver-disease-2026-07-17/
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Air India Seeks About $1.5B In Fresh Equity From Owners Tata Sons And Singapore Airlines, Wants Funds Immediately With Funding Likely In Tranches - Reuters Exclusive
NEW DELHI, Aug 25 (Reuters) - Air India is seeking about $1.5 billion in fresh equity from its owners Tata Sons and Singapore Airlines, months after the second-largest Indian airline posted a record annual loss, two
Charles Schwab Corp Expands Into India With New Hyderabad Office, Targets 2,000-Employee Workforce By End Of 2027
-Reuters
India Wholesale Price Index (WPI) Inflation (YoY) For July 9.78% Vs. 9.95% Est.; 9.87% Prior
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.